Surfactant treatment for acute respiratory distress syndrome

Arch Dis Child. 1999 Mar;80(3):248-52. doi: 10.1136/adc.80.3.248.

Abstract

Objective: To determine prospectively the efficacy of surfactant in acute respiratory distress syndrome.

Study design: Twenty patients, 1 month to 16 years of age, diagnosed with an acute pulmonary disease with severe hypoxaemia (PaO2/FiO2 < 100) (13 with systemic or pulmonary disease and seven with cardiac disease) were treated with one to six doses of 50-200 mg/kg of porcine surfactant administered directly into the trachea. The surfactant was considered to be effective when the PaO2/FiO2 improved by > 20%.

Results: After initial surfactant administration the PaO2/FiO2 increased significantly in patients with systemic or pulmonary disease from 68 to 111, and the oxygenation index (OI) diminished significantly from 36.9 to 27.1. The PaO2/FiO2 and OI did not improve in children with cardiac disease. The improvement of the patients who survived was greater than that of those who died.

Conclusions: Surfactant moderately improves oxygenation in some children with severe acute respiratory distress syndrome secondary to pulmonary or systemic disease.

MeSH terms

  • Adolescent
  • Biological Products*
  • Child
  • Female
  • Heart Diseases / blood
  • Heart Diseases / complications
  • Heart Diseases / surgery
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Oxygen / blood
  • Phospholipids*
  • Postoperative Period
  • Prospective Studies
  • Pulmonary Surfactants / therapeutic use*
  • Respiratory Distress Syndrome / blood
  • Respiratory Distress Syndrome / complications
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome, Newborn / blood
  • Respiratory Distress Syndrome, Newborn / complications
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Statistics, Nonparametric

Substances

  • Biological Products
  • Phospholipids
  • Pulmonary Surfactants
  • poractant alfa
  • Oxygen